Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-024077
Filing Date
2025-08-14
Accepted
2025-08-14 16:31:22
Documents
43
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 619095
2 EX-31.1 ex31-1.htm EX-31.1 11077
3 EX-31.2 ex31-2.htm EX-31.2 11089
4 EX-32.1 ex32-1.htm EX-32.1 5961
5 EX-32.2 ex32-2.htm EX-32.2 6006
  Complete submission text file 0001641172-25-024077.txt   3245883

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mira-20250630.xsd EX-101.SCH 21195
7 XBRL CALCULATION FILE mira-20250630_cal.xml EX-101.CAL 27306
8 XBRL DEFINITION FILE mira-20250630_def.xml EX-101.DEF 108333
9 XBRL LABEL FILE mira-20250630_lab.xml EX-101.LAB 218580
10 XBRL PRESENTATION FILE mira-20250630_pre.xml EX-101.PRE 169109
45 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 428464
Mailing Address 324 SOUTH HYDE PARK AVENUE, SUITE 350 TAMPA FL 33606
Business Address 1200 BRICKELL AVENUE SUITE 1950 #1183 MIAMI FL 33131 813-369-5150
MIRA PHARMACEUTICALS, INC. (Filer) CIK: 0001904286 (see all company filings)

EIN.: 853354547 | State of Incorp.: FL
Type: 10-Q | Act: 34 | File No.: 001-41765 | Film No.: 251219942
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)